Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center

被引:80
作者
Long, KS
Hansen, LH
Jakobsen, L
Vester, B
机构
[1] Univ Copenhagen, Inst Mol Biol & Physiol, DK-1307 Copenhagen K, Denmark
[2] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark
关键词
D O I
10.1128/AAC.50.4.1458-1462.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Tiamulin is a pleuromutilin antibiotic that is used in veterinary medicine. The recently published crystal structure of a tiamulin-50S ribosomal subunit complex provides detailed information about how this drug targets the peptidyl transferase center of the ribosome. To promote rational design of pleuromutilin-based drugs, the binding of the antibiotic pleuromutilin and three semisynthetic derivatives with different side chain extensions has been investigated using chemical footprinting. The nucleotides A2058, A2059, G2505, and U2506 are affected in all of the footprints, suggesting that the drugs are similarly anchored in the binding pocket by the common tricyclic mutilin core. However, varying effects are observed at U2584 and U2585, indicating that the side chain extensions adopt distinct conformations within the cavity and thereby affect the rRNA conformation differently. An Escherichia coli L3 mutant strain is resistant to tiamulin and pleuromutilin, but not valnemulin, implying that valnemulin is better able to withstand an altered rRNA binding surface around the mutilin core. This is likely due to additional interactions made between the valnemulin side chain extension and the rRNA binding site. The data suggest that pleuromutilin drugs with enhanced antimicrobial activity may be obtained by maximizing the number of interactions between the side chain moiety and the peptidyl transferase cavity.
引用
收藏
页码:1458 / 1462
页数:5
相关论文
共 15 条
[1]  
BOCK A, 1982, J BACTERIOL, V151, P1253
[2]   Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein L3 [J].
Bosling, J ;
Poulsen, SM ;
Vester, B ;
Long, KS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2892-2896
[3]   ANTIMICROBIAL ACTIVITIES OF 81.723 HFU, A NEW PLEUROMUTILIN DERIVATIVE [J].
DREWS, J ;
GEORGOPOULOS, A ;
LABER, G ;
SCHUTZE, E ;
UNGER, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 7 (05) :507-516
[4]  
Fossi M, 1999, ACTA VET SCAND, V40, P355
[5]   Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin [J].
Harms, Joerg M. ;
Schluenzen, Frank ;
Fucini, Paola ;
Bartels, Heike ;
Yonath, Ada .
BMC BIOLOGY, 2004, 2 (1)
[6]   Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic [J].
Heilmann, C ;
Jensen, L ;
Jensen, JS ;
Lundstrom, K ;
Windsor, D ;
Windsor, H ;
Webster, D .
JOURNAL OF INFECTION, 2001, 43 (04) :234-238
[7]   Pleuromutilin antibiotics [J].
Hunt, E .
DRUGS OF THE FUTURE, 2000, 25 (11) :1163-1168
[8]   Further characterization of porcine Brachyspira hyodysenteriae isolates with decreased susceptibility to tiamulin [J].
Karlsson, M ;
Aspán, A ;
Landén, A ;
Franklin, A .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (04) :281-285
[9]  
Karlsson M., 2001, Animal Health Research Reviews, V2, P59
[10]   Decreased susceptibility to tiamulin and valnemulin among Czech isolates of Brachyspira hyodysenteriae [J].
Lobová, D ;
Smola, J ;
Cizek, A .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (04) :287-291